Loading
Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.
Iruplinalkib (WX-0593) was developed by Qilu Pharmaceutical in Jinan. The NMPA approved it in June 2023 for locally advanced or metastatic ALK-positive non-small-cell lung cancer that had progressed on or was intolerant to crizotinib, and in 2024 extended the approval to first-line use after the INSPIRE phase 3 trial showed longer progression-free survival than crizotinib.
Blocks the ALK fusion kinase that drives about five percent of non-small-cell lung cancers, including resistance mutations that stop first-generation inhibitors. Connects to ALK and ROS1.
1.Iruplinalkib slips into a pocket on ALK.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2023 | ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024 |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Iruplinalkib" OR ABSTRACT:"Iruplinalkib" OR TITLE:"WX-0593" OR ABSTRACT:"WX-0593" OR TITLE:"Qixinke" OR ABSTRACT:"Qixinke") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iruplinalkib, not a curated reading list.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Non-small-cell lung cancer and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Qilu Pharmaceutical and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.